Regeneron details royalty agreement with Novartis for canakinumab (ACZ885)
Regeneron provided details of the royalty it receives on sales of canakinumab, an anti-IL1β antibody. Under its agreement with Novartis, Regeneron receives a royalty on net sales of canakinumab that starts at 4 percent and reaches 15 percent when canakinumab annual sales exceed $1.5 billion. June 22, 2017